See more : Hanjia Design Group Co., Ltd. (300746.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Vyant Bio, Inc. (VYNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vyant Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Coca-Cola FEMSA, S.A.B. de C.V. (KOFUBL.MX) Income Statement Analysis – Financial Results
- Maccura Biotechnology Co.Ltd (300463.SZ) Income Statement Analysis – Financial Results
- B90 Holdings PLC (B90.L) Income Statement Analysis – Financial Results
- Liberty Global plc (LBTYA) Income Statement Analysis – Financial Results
- Vital Energy Inc. (VUX.V) Income Statement Analysis – Financial Results
Vyant Bio, Inc. (VYNT)
About Vyant Bio, Inc.
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 666.00K | 1.15M | 867.00K | 7.31M | 27.47M | 29.12M | 27.05M | 18.04M | 10.20M | 6.61M | 4.30M | 3.02M | 2.52M | 1.67M |
| Cost of Revenue | 1.01M | 1.85M | 1.10M | 3.70M | 18.72M | 18.07M | 17.10M | 14.10M | 8.45M | 4.92M | 3.93M | 3.12M | 3.52M | 2.53M |
| Gross Profit | -342.00K | -699.00K | -234.00K | 3.60M | 8.75M | 11.05M | 9.95M | 3.94M | 1.75M | 1.69M | 372.57K | -98.00K | -994.61K | -865.93K |
| Gross Profit Ratio | -51.35% | -60.89% | -26.99% | 49.34% | 31.84% | 37.95% | 36.77% | 21.85% | 17.12% | 25.50% | 8.66% | -3.25% | -39.44% | -51.99% |
| Research & Development | 6.77M | 4.27M | 3.23M | 0.00 | 2.49M | 4.79M | 5.97M | 5.48M | 4.62M | 2.19M | 2.11M | 2.07M | 1.17M | 1.34M |
| General & Administrative | 0.00 | 0.00 | 6.60M | 5.17M | 19.18M | 19.89M | 16.03M | 14.57M | 12.37M | 6.12M | 4.50M | 4.44M | 3.45M | 1.84M |
| Selling & Marketing | 8.80M | 8.42M | 2.72M | 1.15M | 5.27M | 4.99M | 4.67M | 5.27M | 3.96M | 1.84M | 1.40M | 1.57M | 715.97K | 239.46K |
| SG&A | 8.80M | 8.42M | 2.72M | 6.32M | 24.45M | 24.88M | 20.70M | 19.84M | 16.33M | 7.96M | 5.90M | 6.01M | 4.16M | 2.08M |
| Other Expenses | 0.00 | 57.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.57M | 12.70M | 5.95M | 6.32M | 26.94M | 29.67M | 26.67M | 25.32M | 20.95M | 10.15M | 8.01M | 8.09M | 5.33M | 3.42M |
| Cost & Expenses | 16.58M | 14.54M | 7.05M | 10.02M | 45.66M | 47.74M | 43.77M | 39.42M | 29.41M | 15.07M | 11.94M | 11.20M | 8.84M | 5.95M |
| Interest Income | 0.00 | 0.00 | 0.00 | 108.00K | 21.00K | 63.00K | 23.00K | 49.00K | 73.80M | 29.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 93.00K | 0.00 | 535.00K | 1.44M | 2.12M | 2.13M | 454.00K | 344.00K | 472.82K | 2.39M | 4.70M | 1.31M | 792.42K | 2.09M |
| Depreciation & Amortization | 843.00K | 8.23M | 2.56M | 757.00K | 2.11M | 2.17M | 2.38M | 1.66M | 838.60K | 326.48K | 353.41K | 13.05K | 537.31K | 3.24K |
| EBITDA | -15.07M | -15.71M | -5.06M | -5.03M | -16.14M | -18.62M | -16.72M | -19.36M | -17.68M | -10.32M | -1.61M | -18.56M | -7.08M | -5.23M |
| EBITDA Ratio | -2,262.61% | -651.39% | -583.85% | -68.80% | -58.75% | -64.10% | -47.96% | -107.33% | -173.36% | -156.16% | -37.46% | -614.68% | -280.68% | -314.18% |
| Operating Income | -15.91M | -15.71M | -7.62M | -2.71M | -18.19M | -18.62M | -16.72M | -21.38M | -19.21M | -8.46M | -7.64M | -8.18M | -6.32M | -4.29M |
| Operating Income Ratio | -2,389.19% | -1,368.12% | -879.24% | -37.14% | -66.23% | -63.95% | -61.83% | -118.50% | -188.34% | -128.01% | -177.62% | -271.08% | -250.76% | -257.31% |
| Total Other Income/Expenses | 105.00K | -2.87M | -1.03M | -4.68M | -2.18M | -4.34M | 921.00K | 9.00K | 215.98K | -4.57M | 974.96K | -11.70M | -2.08M | -3.04M |
| Income Before Tax | -15.81M | -18.58M | -8.65M | -7.40M | -20.37M | -22.96M | -15.80M | -21.37M | -18.99M | -13.04M | -6.67M | -19.89M | -8.41M | -7.33M |
| Income Before Tax Ratio | -2,373.42% | -1,618.03% | -997.69% | -101.26% | -74.16% | -78.84% | -58.42% | -118.45% | -186.22% | -197.22% | -154.96% | -658.64% | -333.42% | -439.96% |
| Income Tax Expense | 6.88M | 27.52M | 546.00K | -512.00K | -59.00K | -2.08M | 1.38M | -1.18M | -2.35M | -663.90K | 5.68M | -10.39M | -1.29M | -950.49K |
| Net Income | -22.69M | -46.10M | -9.20M | -6.71M | -20.37M | -20.88M | -15.80M | -20.18M | -16.64M | -12.37M | -6.67M | -19.89M | -8.41M | -7.33M |
| Net Income Ratio | -3,406.91% | -4,015.24% | -1,060.67% | -91.83% | -74.16% | -71.70% | -58.42% | -111.88% | -163.18% | -187.18% | -154.96% | -658.64% | -333.42% | -439.96% |
| EPS | -3.87 | -10.19 | -18.50 | -17.40 | -111.98 | -151.58 | -149.45 | -294.00 | -264.20 | -397.81 | -278.28 | -381.45 | -350.99 | -305.94 |
| EPS Diluted | -3.87 | -10.19 | -18.50 | -17.40 | -111.98 | -151.58 | -149.45 | -293.97 | -263.85 | -396.90 | -277.98 | -381.45 | -350.61 | -305.61 |
| Weighted Avg Shares Out | 5.87M | 4.53M | 497.20K | 385.60K | 181.94K | 137.75K | 105.74K | 68.65K | 62.99K | 31.10K | 23.95K | 52.14K | 23.95K | 23.95K |
| Weighted Avg Shares Out (Dil) | 5.87M | 4.53M | 497.20K | 385.60K | 181.94K | 137.75K | 105.74K | 68.66K | 63.08K | 31.17K | 23.98K | 52.14K | 23.98K | 23.98K |
Vyant Bio Provides Update on Winddown Activities
CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of...
Vyant Bio Provides Update on Winddown Activities
CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of...
Vyant Bio Announces Stockholder Approval of Plan of Dissolution
CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the “Special Meeting”).
Vyant Bio Announces Completion of StemoniX Asset Sale
CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the “Sale”) pursuant to...
Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders
CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special Meeting”) was reconvened resulting in the approval of the...
Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders
CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Special Meeting”) was reconvened and then adjourned, without conducting...
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Special Meeting”) was reconvened and then adjourned, without conducting...
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the “Special Meeting”) was convened and then adjourned, without conducting...
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets
—Combines Three Leading Human Biomimetic Organoid Platform Technologies for Neurological Drug Discovery— —AxoSim Gains microBrain™ Intellectual Property from StemoniX, Along With Expert Scientific Team and Advanced R&D and Manufacturing Facility in Minnesota— —AxoSim to Begin Offering microBrain Products and Services Under...
Vyant Bio to pursue listing on OTC Pink Open Market
Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist from the exchange.
Source: https://incomestatements.info
Category: Stock Reports